Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression

Ge,Qianqian; Zhou,Jia; Tu,Min; Xue,Xiaofeng; Li,Zhanjun; Lu,Zipeng; Wei,Jishu; Song,Guoxin; Chen,Jianmin; Guo,Feng; Jiang,Kuirong; Miao,Yi; Gao,Wentao

doi:10.3892/or.2015.4127

Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression

Authors:
- Qianqian Ge
- Jia Zhou
- Min Tu
- Xiaofeng Xue
- Zhanjun Li
- Zipeng Lu
- Jishu Wei
- Guoxin Song
- Jianmin Chen
- Feng Guo
- Kuirong Jiang
- Yi Miao
- Wentao Gao
View Affiliations

Affiliations: Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China, The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, P.R. China, Department of General Surgery, The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, P.R. China, Department of Pathology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. China
Published online on: July 13, 2015 https://doi.org/10.3892/or.2015.4127
Pages: 1327-1336

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a member of the vasohibin (VASH2) family, VASH2 is localized intracellularly as a nuclear and cytoplasmic type. Cytoplasmic VASH2 is associated with carcinoma angiogenesis and malignant transformation and promotes cancer growth. However, the function of nuclear VASH2 has yet to be investigated. The aim of the present study was to detect the nuclear VASH2 expression profile in human organs and tissues by protein microarray technique. To examine the function of nuclear VASH2, we analyzed the relationship between nuclear VASH2 and Ki-67, and stably constructed VASH2 overexpression and knockdown in LO2 and HepG2 cell lines, based on a previous study in hepatic cells. The study was conducted using bromodeoxyuridine, immunofluorescent staining, western blot analysis and flow cytometry. Nuclear VASH2 was highly expressed in actively dividing cells in normal and cancer tissues. There was a significant positive correlation between nuclear VASH2 and Ki-67, indicating that nuclear VASH2 positively correlated with cell proliferation in normal and cancer tissues. The bromodeoxyuridine (BrdU) proliferation test showed that nuclear VASH2 increased the S-phase population and promoted cell proliferation, while VASH2 knockdown reduced BrdU absorbance. Cell cycle analysis revealed that nuclear VASH2 overexpression increased the S-phase population in LO2 and HepG2 cells, while nuclear VASH2 knockdown reduced the S-phase population and increased the G0/G1 population. The findings of this study challenge the classic view of VASH2, which was previously reported as an angiogenesis factor. Furthermore, to the best of our knowledge, these results are the first clinical data indicating that nuclear VASH2, but not cytoplasmic VASH2, promotes cell proliferation by driving the cell cycle from the G0/G1 to S phase.

View Figures

View References

1	Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H, Shimosegawa T, et al: Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol. 26:1051–1057. 2006. View Article : Google Scholar : PubMed/NCBI
2	Suzuki Y, Kobayashi M, Miyashita H, Ohta H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J Cell Sci. 123:3094–3101. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sato Y: The vasohibin family: A novel family for angiogenesis regulation. J Biochem. 153:5–11. 2013. View Article : Google Scholar
4	Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, Zhang Y, Sun J, Wei J, Lu Z, et al: Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 32:1724–1734. 2013. View Article : Google Scholar
5	Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, Suzuki M and Sato Y: Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 10:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
6	Koyanagi T, Saga Y, Takahashi Y, Suzuki Y, Suzuki M and Sato Y: Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol Lett. 5:1058–1062. 2013.PubMed/NCBI
7	Tu M, Liu X, Han B, Ge Q, Li Z, Lu Z, Wei J, Song G, Cai B, Lv N, et al: Vasohibin-2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor-2 and growth/differentiation factor-15 expression. Mol Med Rep. 10:663–669. 2014.PubMed/NCBI
8	Li Z, Tu M, Han B, Gu Y, Xue X, Sun J, Ge Q, Miao Y, Qian Z and Gao W: Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53. PLoS One. 9:e903582014. View Article : Google Scholar : PubMed/NCBI
9	Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M and Sato Y: In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci. 104:1705–1710. 2013. View Article : Google Scholar : PubMed/NCBI
10	Sun J, Tu M, Han B, Xue X, Zhang Y, Wei J, Chen J, Lu Z, An Y, Cai B, et al: Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization. Int J Oncol. 43:255–261. 2013.PubMed/NCBI
11	Tang S, Wang Y, Zhang D, Gao Y, Ma Y, Yin B, Sun J, Liu J and Zhang Y: Reprogramming donor cells with oocyte extracts improves in vitro development of nuclear transfer embryos. Anim Reprod Sci. 115:1–9. 2009. View Article : Google Scholar
12	Lin J, Lin X, Yang GH, Wang Y, Peng BW and Lin JY: Toxoplasma gondii: Expression of GRA1 gene in endoplasmic reticulum promotes both growth and adherence and modulates intracellular calcium release in macrophages. Exp Parasitol. 125:165–171. 2010. View Article : Google Scholar : PubMed/NCBI
13	Dolbeare F: Bromodeoxyuridine: A diagnostic tool in biology and medicine, part III. proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Histochem J. 28:531–575. 1996. View Article : Google Scholar : PubMed/NCBI
14	Danova M, Riccardi A and Mazzini G: Cell cycle-related proteins and flow cytometry. Haematologica. 75:252–264. 1990.PubMed/NCBI
15	Scholzen T and Gerdes J: The Ki-67 protein: From the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
16	Cohen SM, Ohnishi T, Clark NM, He J and Arnold LL: Investigations of rodent urinary bladder carcinogens: Collection, processing, and evaluation of urine and bladders. Toxicol Pathol. 35:337–347. 2007. View Article : Google Scholar : PubMed/NCBI
17	Dwivedi N, Chandra S, Kashyap B, Raj V and Agarwal A: Suprabasal expression of Ki-67 as a marker for the severity of oral epithelial dysplasia and oral squamous cell carcinoma. Contemp Clin Dent. 4:7–12. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kramer E, Herman O, Frand J, Leibou L, Schreiber L and Vaknine H: Ki67 as a biologic marker of basal cell carcinoma: A retrospective study. Isr Med Assoc J. 16:229–232. 2014.PubMed/NCBI
19	Luo Y, Kleiboeker S, Deng X and Qiu J: Human parvovirus B19 infection causes cell cycle arrest of human erythroid progenitors at late S phase that favors viral DNA replication. J Virol. 87:12766–12775. 2013. View Article : Google Scholar : PubMed/NCBI
20	Robertson DS: The development of tumor cell characteristics. J Cell Physiol. 229:705–710. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zhao P, Fu JL, Yao BY, Jia YR and Zhou ZC: S phase cell percentage normalized BrdU incorporation rate, a new parameter for determining S arrest. Biomed Environ Sci. 27:215–219. 2014.PubMed/NCBI
22	Bahrami F, Morris DL, Rufener L and Pourgholami MH: Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. Am J Cancer Res. 4:545–557. 2014.PubMed/NCBI